Effect of design specifications in dose‐finding trials for combination therapies in oncology

Model‐based dose‐finding methods for a combination therapy involving two agents in phase I oncology trials typically include four design aspects namely, size of the patient cohort, three‐parameter dose‐toxicity model, choice of start‐up rule, and whether or not to include a restriction on dose‐level skipping. The effect of each design aspect on the operating characteristics of the dose‐finding method has not been adequately studied. However, some studies compared the performance of rival dose‐finding methods using design aspects outlined by the original studies. In this study, we featured the well‐known four design aspects and evaluated the impact of each independent effect on the operating characteristics of the dose‐finding method including these aspects. We performed simulation studies to examine the effect of these design aspects on the determination of the true maximum tolerated dose combinations as well as exposure to unacceptable toxic dose combinations. The results demonstrated that the selection rates of maximum tolerated dose combinations and UTDCs vary depending on the patient cohort size and restrictions on dose‐level skipping However, the three‐parameter dose‐toxicity models and start‐up rules did not affect these parameters. Copyright © 2016 John Wiley & Sons, Ltd.     

Potential Uncertainty Reduction in Model‐Averaged Benchmark Dose Estimates Informed by an Additional Dose Study

A methodology is presented for assessing the information value of an additional dosage experiment in existing bioassay studies. The analysis demonstrates the potential reduction in the uncertainty of toxicity metrics derived from expanded studies, providing insights for future studies. Bayesian methods are used to fit alternative dose‐response models using Markov chain Monte Carlo (MCMC) simulation for parameter estimation and Bayesian model averaging (BMA) is used to compare and combine the alternative models. BMA predictions for benchmark dose (BMD) are developed, with uncertainty in these predictions used to derive the lower bound BMDL. The MCMC and BMA results provide a basis for a subsequent Monte Carlo analysis that backcasts the dosage where an additional test group would have been most beneficial in reducing the uncertainty in the BMD prediction, along with the magnitude of the expected uncertainty reduction. Uncertainty reductions are measured in terms of reduced interval widths of predicted BMD values and increases in BMDL values that occur as a result of this reduced uncertainty. The methodology is illustrated using two existing data sets for TCDD carcinogenicity, fitted with two alternative dose‐response models (logistic and quantal‐linear). The example shows that an additional dose at a relatively high value would have been most effective for reducing the uncertainty in BMA BMD estimates, with predicted reductions in the widths of uncertainty intervals of approximately 30%, and expected increases in BMDL values of 5–10%. The results demonstrate that dose selection for studies that subsequently inform dose‐response models can benefit from consideration of how these models will be fit, combined, and interpreted.     

Animal and Human Dose‐Response Models for Brucella Species

Human Brucellosis is one of the most common zoonotic diseases worldwide. Disease transmission often occurs through the handling of domestic livestock, as well as ingestion of unpasteurized milk and cheese, but can have enhanced infectivity if aerosolized. Because there is no human vaccine available, rising concerns about the threat of Brucellosis to human health and its inclusion in the Center for Disease Control's Category B Bioterrorism/Select Agent List make a better understanding of the dose‐response relationship of this microbe necessary. Through an extensive peer‐reviewed literature search, candidate dose‐response data were appraised so as to surpass certain standards for quality. The statistical programming language, “R,” was used to compute the maximum likelihood estimation to fit two models, the exponential and the approximate beta‐Poisson (widely used for quantitative risk assessment) to dose‐response data. Dose‐response models were generated for prevalent species of Brucella: Br. suis, Br. melitensis, and Br. abortus. Dose‐response models were created for aerosolized Br. suis exposure to guinea pigs from pooled studies. A parallel model for guinea pigs inoculated through both aerosol and subcutaneous routes with Br. melitensis showed that the median infectious dose corresponded to a 30 colony‐forming units (CFU) dose of Br. suis, much less than the N₅₀ dose of about 94 CFU for Br. melitensis organisms. When Br. melitensis was tested subcutaneously on mice, the N₅₀ dose was higher, 1,840 CFU. A dose‐response model was constructed from pooled data for mice, rhesus macaques, and humans inoculated through three routes (subcutaneously/aerosol/intradermally) with Br. melitensis.     

Optimal Experimental Design Strategies for Detecting Hormesis

Hormesis is a widely observed phenomenon in many branches of life sciences, ranging from toxicology studies to agronomy, with obvious public health and risk assessment implications. We address optimal experimental design strategies for determining the presence of hormesis in a controlled environment using the recently proposed Hunt‐Bowman model. We propose alternative models that have an implicit hormetic threshold, discuss their advantages over current models, and construct and study properties of optimal designs for (i) estimating model parameters, (ii) estimating the threshold dose, and (iii) testing for the presence of hormesis. We also determine maximin optimal designs that maximize the minimum of the design efficiencies when we have multiple design criteria or there is model uncertainty where we have a few plausible models of interest. We apply these optimal design strategies to a teratology study and show that the proposed designs outperform the implemented design by a wide margin for many situations.     

金融资产管理公司的市场结构与绩效

运用现代产业组织的“有效结构假说”等相关理论,对形成金融资产管理公司不良资产的结构性因素包括市场份额、市场集中度和市场壁垒等项关联指标进行分析,同时对财政部经营目标的完成情况进行对比分析。分析认为,垄断型的市场结构是制约资产管理公司提高经营绩效的重要因素。分析结果表明：要不断提升资产管理公司的经营绩效必须改变其市场结构,加强公司的约束机制与激励机制建设。     

当前我国声乐教学状况及其改变对策

文章分析了我国目前声乐教学存在的不足，并针对性的提出了几条解决的办法和建议，以期声乐教学能达到最佳效果，为祖国培养更多声乐人才。     

水稻种衣剂禾盛3号应用效果初探

水稻种衣剂禾盛 3号包衣后对种子室内发芽率有一定的抑制作用 ,浓度越大 ,发芽率降低越多 ,对秧苗素质和收获产量有一定的促进作用 ,特别是对苗期稻蓟马危害的防治 ,效果明显 ,达 79.7%～ 95 .8% ,使用浓度以药种质量比 1∶5 0或 1∶2 5的效果较好     

Incorporating historical information to improve phase I clinical trials

Incorporating historical data has a great potential to improve the efficiency of phase I clinical trials and to accelerate drug development. For model-based designs, such as the continuous reassessment method (CRM), this can be conveniently carried out by specifying a “skeleton,” that is, the prior estimate of dose limiting toxicity (DLT) probability at each dose. In contrast, little work has been done to incorporate historical data into model-assisted designs, such as the Bayesian optimal interval (BOIN), Keyboard, and modified toxicity probability interval (mTPI) designs. This has led to the misconception that model-assisted designs cannot incorporate prior information. In this paper, we propose a unified framework that allows for incorporating historical data into model-assisted designs. The proposed approach uses the well-established “skeleton” approach, combined with the concept of prior effective sample size, thus it is easy to understand and use. More importantly, our approach maintains the hallmark of model-assisted designs: simplicity—the dose escalation/de-escalation rule can be tabulated prior to the trial conduct. Extensive simulation studies show that the proposed method can effectively incorporate prior information to improve the operating characteristics of model-assisted designs, similarly to model-based designs.     

写字评价方式与作用探析

培养学生良好的写字习惯,指导学生写好汉字,是小学阶段教学的重要任务。合理运用比较评价、激励评价、展示评价、写字升级等多元写字评价方法,是激发学生写字兴趣,提高写字评价对写字教学促进作用的有效途径。